Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Corvus Pharmaceuticals ( (CRVS) ) has shared an announcement.
Corvus Pharmaceuticals announced new interim data from its Phase 1 clinical trial of soquelitinib for treating atopic dermatitis, showing a favorable safety and efficacy profile. The data revealed significant improvements in clinically meaningful endpoints compared to placebo, with no safety issues observed, positioning soquelitinib as a potential new treatment for immune diseases.
More about Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focusing on developing ITK inhibition as a novel immunotherapy approach for various cancer and immune diseases. Its lead product candidate, soquelitinib, is an investigational oral small molecule drug aimed at selectively inhibiting ITK.
YTD Price Performance: -1.84%
Average Trading Volume: 1,185,994
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $342.5M
See more data about CRVS stock on TipRanks’ Stock Analysis page.
